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surgical history, ophthalmic medications, visual acuity, visual
ﬁeld parameters, and intraocular pressures. Economic data,
including physician visits (ophthalmologist/optometrist), diag-
nostic and monitoring tests, glaucoma medications, medical and
surgical procedures, and specialized glaucoma-related services,
were obtained from patient-level billing and reimbursement
records. Specialized LVC services collected via the chart review
for clinical and economic analysis included utilization of low-
vision devices (e.g., CCTV and magnifying devices), patient 
education and counseling for lifestyle modiﬁcations (e.g., glare
strategies and mobility training), and social/support services.
RESULTS: Of the 61 patients reviewed, 42% were male. The
mean age of the sample cohort was 75 years (minimum 33 years
to a maximum of 93 years). Of the 28 patients with applicable
data, 54% had a family history of glaucoma. Comorbid condi-
tions among the sample patients were hypertension (47%) and
diabetes (12%). The breakdown of payment type was 56%
Medicare and 21% Medicaid. At the same time, 33% of patients
had private coverage and 8% paid for their services out-of-
pocket. Mean direct cost of care was $1960 per patient during
the ﬁrst year of LVC, with 22.6% attributable to LVC. CON-
CLUSIONS: LVC contributed to the healthcare utilization and
direct costs of treating end-stage glaucoma patients.
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OBJECTIVES: To examine blindness-related comorbidities in a
Medicare population with primary open angle glaucoma
(POAG), speciﬁcally fractures (including hip, femoral, and ver-
tebral fractures) and depression (including several types of
depressive/neurotic conditions), and their association with being
diagnosed as blind. A secondary objective is to examine the total
Medicare-related healthcare spending between non-blind and
blind glaucoma patients relative to comorbidities. METHODS:
The data source was a Medicare 5% Sample of 1998 Glaucoma
Patients with and without blindness (n = 70,060). Odds ratios
(OR) were created from the annual prevalence rates of fractures
and depression between blind and non-blind groups. Multiple
propensity scoring methods were used to account for selection
bias in those patients coded for blindness. Comparisons were
conducted between blind (cases) and non-blind (controls) groups
before and after matching cases to controls by propensity score.
Matched and unmatched results were also stratiﬁed by age, sex,
and Charlson Comorbidity Index scores. Medicare reimburse-
ments were compared between groups using non-parametric sta-
tistical methods. RESULTS: The overall matched odds ratios for
depression and depressive disorders in the blind group were 1.88
(95% CI: 1.08–3.28) and 1.63 (95% CI: 1.05–2.52), respec-
tively. Hip fractures had a signiﬁcant OR 4.86, (95% CI:
1.158–20.36) speciﬁcally in the unmatched 65–69 year-old
cohort but not in the matched. Total age-adjusted non-eye
related Medicare costs were signiﬁcantly greater in the blind
group ($2510 vs. $1784). The mean annual cost for depression
related procedures/visits for those diagnosed with depression was
$411 in the blind group vs. $185 in the non-blind group. CON-
CLUSIONS: There is an association with being blind in a glau-
coma population and having a greater risk for depression and
fractures (in younger cohorts). The blind glaucoma population
has greater age-adjusted eye-related and total (non-eye-related)
Medicare costs than non-blind glaucoma subjects.
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OBJECTIVES: The non-medical costs of visual impairment to
individuals and the nation are largely unknown. Data produced
by state agencies are not relevant. Knowledge of these costs is
essential when allocating resources to therapeutic or preventa-
tive programs. METHODS: We analysed two representative
nation-wide surveys of 14,603 subjects living in institutions, and
16,945 in the community, with the object of documenting hand-
icap. Subjects were classiﬁed as blind (no light perception), low
vision (LV: loss of shape perception), or control. We also costed
the following items: family income, social allowances, devices,
home modiﬁcation, paid assistance, time spent by carers and
unmet needs. Next, we standardised item consumption on con-
founding factors, using logistic regression. Lastly, unit costs
attributable to visual impairment were estimated and compared
with the costs incurred by control subjects. Our economic stand-
point was that of society. RESULTS: The national non-medical
costs attributable to LV (9438€m; 14,659€m with unmet needs)
accounted for almost the entire costs of visual impairment
(10,749€m; 1630€2m with unmet needs). However, the average
annual cost/patient was 7826€ for LV (12,154€ with unmet
needs) versus 19,173€ for blindness (24,036€ with unmet needs).
Lost family income amounted to 4552€m and the carers’ burden
to 2525€m. In addition, 5080€m of social allowances were not
distributed because many blind people do not register. CON-
CLUSIONS: Indemniﬁcation of visual handicap should cover
total non-medical costs including the predominant unmet needs.
Thus strategies of resource allocation, intended to alleviate visual
impairment, should include all economic dimensions, extending
to non-medical items.
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OBJECTIVES: To estimate nursing time and costs attributable
to visual impairment from a questionnaire documenting activi-
ties of daily living (ADLs) in France. METHODS: 356,208 citi-
zens in the general community were selected at random. A
sub-sample of 16,945 subjects (blind, low vision and control)
was further selected randomly and interviewed. The ADL ques-
tionnaire was comprised of more than 30 items, including
washing, cooking, mobility, shopping, cleaning, etc. A factor
analysis was performed and six clusters were identiﬁed: hygiene
and meals; physical capacity; transport and housework; ability
to move; behavioral problems; and autonomy. Three levels of
dependency were predeﬁned for each cluster: none; subject
required partial help; subject required complete help. A subset
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of 128 scenarios was selected from 729 possible scenarios (3
power 6) in order to test second-order interactions. Interviews
with 21 healthcare professionals (nurses and nursing auxiliaries)
ascertained the duration of assistance required for 18 of the 128
scenarios, selected at random. The economic perspective was
that of society. The link between time spent, costs, and factor
scores was derived from linear and non-linear models. These
functions were applied to the 16,945 subjects in order to esti-
mate the assistance time required. Comparisons between blind,
low vision and control subjects were performed using an
ANOVA with adjustments for age, number of people in the
household, and number of handicaps. RESULTS: Average care-
hours per annum were 682.7 for blind people, 261.4 hours for
low vision subjects, and 147.5 for controls. The annual care
budget was 6750€ for blind subjects, and 1463€ for subjects with
low vision. The total mean yearly nationwide care cost to fami-
lies for visual impairment was estimated at 2025.9€m. CON-
CLUSIONS: Screening and treatment programs aimed at
preserving vision should beneﬁt society and would help to reduce
expenditures on assistance time due to visual impairment.
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OBJECTIVES: To estimate the non-medical costs related to
visual impairment in four European countries. METHODS:
Counts of visually impaired people, deﬁned according to local
rules, were extracted from National Registers, and for France
from two recent nation-wide surveys realized by INSEE. Esti-
mated numbers of non-registered persons were based on the lit-
erature and expert opinion. Estimation of non-medical cost
included stay in institution, medical devices, home adaptations,
burden on carer, paid home help, loss of income and social
allowances related to visual impairment. Unit costs were
obtained from National databases, local manufacturers and the
Web. Also, in France, interviews were conducted on 21 health-
care professionals to estimate the duration of assistance required
by visually impaired people. These durations were used to eval-
uate the cost of paid home help in each of the four countries.
RESULTS: Visually impaired subjects in France, Germany, Italy
and the UK numbered, respectively, 1.27, 0.73, 1.03 and 1.11
million, including 55,9%, 10%, 80%, and 64% non-registered
persons. The institutionalization rate of visually impaired
persons were 7.8%, 9.6%, 10.9% and 10.0%, respectively. Total
annual costs for visually impaired people were estimated at
10,749€m, 9338€m, 12,069€m, and 15,180€m in France,
Germany, Italy and the UK, respectively. The main costs attrib-
utable to visual impairment were “loss of income” (22.6% to
42.5%), “burden on carer” (23.5% to 38.6%), “paid assistance”
(12.4% to 27.8%) and “social allowances” (4.8% to 8.8%).
CONCLUSIONS: The total non-medical costs attributable to
visual impairment are considerable, amounting to 8.1%, 4.7%,
12.4%, and 14.9% of the National Health expenditure of
France, Germany, Italy and the UK, respectively. However, they
were under-estimated because many blind people were not reg-
istered. Also, the total costs did not include allowances that
should have been paid to non-registered persons.
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OBJECTIVES: To compare the cost of disposable items used
during cataract surgery with and without Custom Pak ® in two
French public centres. METHODS: Custom Pak ® is a cus-
tomised package that provides all the necessary disposable
devices speciﬁed by a surgeon for cataract surgery in one sterile
bag. An exploratory time and motion analysis of cataract surg-
eries at two well-known French public centres was carried out
to compare operations performed with the customized versus
regular set ups. The time and category of employees involved
during the cataract surgery was recorded from the start to the
ﬁnish of the operation. Moreover, the time costs of profession-
als was calculated from available information. The potential for
increasing turnover to the hospitals was also estimated.
RESULTS: The main time savings beneﬁt with the Custom Pak®
was observed during the preparation phase of the cataract sur-
gical intervention. The mean time of surgical preparation was
decreased by 10.45 minutes with a total time deceased of 16.15
minutes for the individual surgeon. The savings associated with
this gain in time was estimated to be 17.63€ as compared with
an incremental Custom Pak ® cost of 11.30€. During one oper-
ating session of 4 hours, the Custom Pak ® allowed the hospi-
tals to perform 1.02 more cataract operations (n = 4.36 cataract
operations without Custom Pak® and n = 5.38 cataract opera-
tions with Custom Pak®) and to increase the overall hospital
turn-over by 1863€, that is, the amount paid for this extra
cataract surgery to the public hospital at an additional costs of
61€ for Custom Pak® devices. CONCLUSIONS: Overall, the
Custom Pak ® increases the productivity and potential for
turnover associated with performing cataract surgery. This
increased turnover easily exceeds the extra cost of the customized
package.
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OBJECTIVES: To analyze the prevalence of local antiglaucoma
medicines in drug-store of Russia and to make the pharmaeco-
nomical research on the base of large statistical selection.
METHODS: In 2003, the total cost of antiglaucoma medicines
sales in drug-stores of Russia was about 10.86m USD. The beta-
blockers took the ﬁrst place ($7.0m or 64.4%. The pilocarpine
analogue medicines took the second place. Their joint sales
volume was $1.8m or 16.7%. Two combined medicines Fotil
and Fotil forte (Santen) were at the third place $1.2m (10.7%).
Latanoprost (Xalatan, Pharmacia-Pﬁzer) and Brinzolamide
(Azopt, Alcon) began to be saled more active. The sales of the
ﬁrst, in 2003, were 3.8%. Azopt began to be saled only in 2002
and its results are $147,878.15 or 1.35% and in 2003—
$289,265 (2.7%) The other CAI Trusopt (MSD) was pharma-
coeconomical in 2002 on $217,473.86 (1.99%) and in 2003
$184,713 (1.7%). The portion of all other medicines in 2002
was less than 0.5%. The average price of beta-blocers is 0.7-
$2.1, CAIs about $22; prostaglandins and their combination
(Xalacom, Pﬁzer—sales started only in the end of 2002 year in
Russian market) $25.6 and $26.9; combined form (timolol +
pilocarpine) $5; pilocarpine $0.83 round the clock and the
course of treatment during a one year is $11.92 (pilocarpine)
$380.32 (Trusopt). RESULTS: The timolol maleate, pilocarpine
